Vasculitis

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 2 SUPPL. 2, 2010, Pages

  Langford, Carol A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DAPSONE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RIBAVIRIN; RITUXIMAB;

ADD ON THERAPY; ANAPHYLACTOID PURPURA; AORTA ARCH SYNDROME; ARTICLE; BEHCET DISEASE; BLADDER CARCINOMA; BLADDER INJURY; BONE MARROW SUPPRESSION; BRAIN ISCHEMIA; BRAIN VASCULITIS; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CRYOGLOBULINEMIC VASCULITIS; CUTANEOUS VASCULITIS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; GIANT CELL ARTERITIS; GLOMERULONEPHRITIS; HUMAN; INFERTILITY; MICROSCOPIC POLYANGIITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYELOPROLIFERATIVE DISORDER; PATHOPHYSIOLOGY; POLYARTERITIS NODOSA; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOPSY; BLOOD VESSELS; CONSTRICTION, PATHOLOGIC; GRANULOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; VASCULITIS;

EID: 76749139809     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.07.002     Document Type: Article

References (55)

1. Hunder G.G., Arend W.P., Bloch D.A., Calabrese L.H., Fauci A.S., Fries J.F., et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 33 (1990) 1065-1067
2. Jennette J.C., Falk R.J., Andrassy K., Bacon P.A., Churg J., Gross W.L., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 (1994) 187-192
3. Weyand C.M., and Goronzy J.J. Medium- and large-vessel vasculitis. N Engl J Med 349 (2003) 160-169
4. Kallenberg C.G. Pathogenesis of PR3-ANCA associated vasculitis. J Autoimmun 30 (2008) 29-36
5. Bosch X., Guilabert A., and Font J. Antineutrophil cytoplasmic antibodies. Lancet 368 (2006) 404-418
6. Langford C.A. The diagnostic utility of c-ANCA in Wegener's granulomatosis. Cleve Clin J Med 65 (1998) 135-140
7. Finkielman J.D., Merkel P.A., Schroeder D., Hoffman G.S., Spiera R., St Clair E.W., et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 147 (2007) 611-619
8. Salvarani C., Cantini F., Boiardi L., and Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347 (2002) 261-271
9. Calamia K.T., and Hunder G.G. Clinical manifestations of giant cell (temporal) arteritis. Clin Rheum Dis 6 (1980) 389-403
10. Nuenninghoff D.M., Hunder G.G., Christianson T.J., McClelland R.L., and Matteson E.L. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 48 (2003) 3532-3537
11. Aiello P.D., Trautmann J.C., McPhee T.J., Kunselman A.R., and Hunder G.G. Visual prognosis in giant cell arteritis. Ophthalmology 100 (1993) 550-555
12. Proven A., Gabriel S.E., Orces C., O'Fallon W.M., and Hunder G.G. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 49 (2003) 703-708
13. Nesher G., Berkun Y., Mates M., Baras M., Rubinow A., and Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 50 (2004) 1332-1337
14. Lee M.S., Smith S.D., Galor A., and Hoffman G.S. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 54 (2006) 3306-3309
15. Jover J.A., Hernandez-Garcia C., Morado I.C., Vargas E., Banares A., and Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 134 (2001) 106-114
16. Hoffman G.S., Cid M.C., Hellmann D.B., Guillevin L., Stone J.H., Schousboe J., et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46 (2002) 1309-1318
17. Mahr A.D., Jover J.A., Spiera R.F., Hernandez-Garcia C., Fernandez-Gutierrez B., Lavalley M.P., et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56 (2007) 2789-2797
18. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., Merkel P.A., Weyand C.M., Stone J.H., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146 (2007) 621-630
19. Salvarani C., Macchioni P., Manzini C., Paolazzi G., Trotta A., Manganelli P., et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 146 (2007) 631-639
20. Kerr G.S., Hallahan C.W., Giordano J., Leavitt R.Y., Fauci A.S., Rottem M., et al. Takayasu arteritis. Ann Intern Med 120 (1994) 919-929
21. Maksimowicz-McKinnon K., Clark T.M., and Hoffman G.S. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 56 (2007) 1000-1009
22. Hoffman G.S., Leavitt R.Y., Kerr G.S., Rottem M., Sneller M.C., and Fauci A.S. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37 (1994) 578-582
23. Molloy E.S., Langford C.A., Clark T.M., Gota C.E., and Hoffman G.S. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 67 (2008) 1567-1569
24. Mouthon L., Le Toumelin P., Andre M.H., Gayraud M., Casassus P., and Guillevin L. Polyarteritis nodosa and Churg-Strauss angiitis: characteristics and outcome in 38 patients over 65 years. Medicine (Baltimore) 81 (2002) 27-40
25. Gayraud M., Guillevin L., le Toumelin P., Cohen P., Lhote F., Casassus P., et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44 (2001) 666-675
26. Guillevin L., Mahr A., Callard P., Godmer P., Pagnoux C., Leray E., et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 84 (2005) 313-322
27. Hoffman G.S., Kerr G.S., Leavitt R.Y., Hallahan C.W., Lebovics R.S., Travis W.D., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116 (1992) 488-498
28. Langford C.A., Talar-Williams C., Barron K.S., and Sneller M.C. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 114 (2003) 463-469
29. Jayne D., Rasmussen N., Andrassy K., Bacon P., Tervaert J.W., Dadoniene J., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349 (2003) 36-44
30. Pagnoux C., Mahr A., Hamidou M.A., Boffa J.J., Ruivard M., Ducroix J.P., et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359 (2008) 2790-2803
31. De Groot K., Rasmussen N., Bacon P.A., Tervaert J.W., Feighery C., Gregorini G., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 2461-2469
32. Jayne D.R., Gaskin G., Rasmussen N., Abramowicz D., Ferrario F., Guillevin L., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18 (2007) 2180-2188
33. Nataraja A., Mukhtyar C., Hellmich B., Langford C., and Luqmani R. Outpatient assessment of systemic vasculitis. Best Pract Res Clin Rheumatol 21 (2007) 713-732
34. Wegener's Granulomatosis Etanercept Trial Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352 (2005) 351-361
35. Keogh K.A., Wylam M.E., Stone J.H., and Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 262-268
36. Guillevin L., Durand-Gasselin B., Cevallos R., Gayraud M., Lhote F., Callard P., et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42 (1999) 421-430
37. Guillevin L., Cohen P., Gayraud M., Lhote F., Jarrousse B., and Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 78 (1999) 26-37
38. Keogh K.A., and Specks U. Churg-Strauss syndrome. Semin Respir Crit Care Med 27 (2006) 148-157
39. Ribi C., Cohen P., Pagnoux C., Mahr A., Arene J.P., Lauque D., et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 58 (2008) 586-594
40. Chen K.R., and Carlson J.A. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 9 (2008) 71-92
41. Gibson L.E. Cutaneous vasculitis update. Dermatol Clin 19 (2001) 603-615 vii
42. Lamprecht P., Gause A., and Gross W.L. Cryoglobulinemic vasculitis. Arthritis Rheum 42 (1999) 2507-2516
43. Cacoub P., and Saadoun D. Hepatitis C virus infection induced vasculitis. Clin Rev Allergy Immunol 35 (2008) 30-39
44. Saadoun D., Delluc A., Piette J.C., and Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 20 (2008) 23-28
45. Vassilopoulos D., and Calabrese L.H. Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies. Arthritis Rheum 46 (2002) 585-597
46. Saulsbury F.T. Henoch-Schonlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore) 78 (1999) 395-409
47. Meadow S.R., Glasgow E.F., White R.H.R., Moncrieff M.W., Cameron J.S., and Ogg C.S. Schonlein-Henoch nephritis. QJM 41 (1972) 241-258
48. Barron K.S., Shulman S.T., Rowley A., Taubert K., Myones B.L., Meissner H.C., et al. Report of the National Institutes of Health Workshop on Kawasaki Disease. J Rheumatol 26 (1999) 170-190
49. Newburger J.W., Takahashi M., Beiser A.S., Burns J.C., Bastian J., Chung K.J., et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324 (1991) 1633-1639
50. Calamia K.T., and Kaklamanis P.G. Behcet's disease: recent advances in early diagnosis and effective treatment. Curr Rheumatol Rep 10 (2008) 349-355
51. Yurdakul S., and Yazici H. Behcet's syndrome. Best Pract Res Clin Rheumatol 22 (2008) 793-809
52. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 335 (1990) 1078-1080
53. Hajj-Ali R.A., and Calabrese L.H. Central nervous system vasculitis. Curr Opin Rheumatol 21 (2009) 10-18
54. Salvarani C., Brown Jr. R.D., Calamia K.T., Christianson T.J., Weigand S.D., Miller D.V., et al. Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol 62 (2007) 442-451
55. Calabrese L.H., Dodick D.W., Schwedt T.J., and Singhal A.B. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med 146 (2007) 34-44